FindTrial
Sign In

mRNA-1010

BIOLOGICAL14 trials

Sponsors

ModernaTX, Inc.

Conditions

CytomegalovirusInfluenzaRSVRespiratory Syncytial VirusSARS-CoV-2Seasonal Influenza

Phase 1

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
CompletedNCT04956575
ModernaTX, Inc.Seasonal Influenza
Start: 2021-07-06End: 2022-09-27Updated: 2023-10-27
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
CompletedNCT05333289
ModernaTX, Inc.Seasonal Influenza
Start: 2022-04-06End: 2022-11-22Updated: 2024-02-01
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
CompletedNCT05375838
ModernaTX, Inc.Influenza, SARS-CoV-2
Start: 2022-05-13End: 2022-12-29Updated: 2024-02-28
A Study of Modified mRNA Vaccines in Healthy Adults
CompletedNCT05397223
ModernaTX, Inc.Cytomegalovirus, Respiratory Syncytial Virus, SARS-CoV-2 +1
Start: 2022-05-24End: 2026-02-27Updated: 2026-03-12
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
CompletedNCT05585632
ModernaTX, Inc.Influenza, RSV, SARS-CoV-2
Start: 2022-10-14End: 2024-02-28Updated: 2024-03-08
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
CompletedNCT05827068
ModernaTX, Inc.Seasonal Influenza
Start: 2023-03-27End: 2023-11-20Updated: 2025-02-03
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
RecruitingNCT07870330
ModernaTX, Inc.Seasonal Influenza
Start: 2026-10-07End: 2027-12-07Target: 96Updated: 2026-10-28

Phase 2

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults
CompletedNCT05606965
ModernaTX, Inc.Influenza
Start: 2022-11-02End: 2025-11-13Updated: 2025-11-24
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults
CompletedNCT05868382
ModernaTX, Inc.Influenza
Start: 2023-05-15End: 2023-12-19Updated: 2024-12-20

Phase 3

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
CompletedNCT05415462
ModernaTX, Inc.Seasonal Influenza
Start: 2022-06-06End: 2023-09-04Updated: 2024-09-24
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
CompletedNCT05566639
ModernaTX, Inc.Seasonal Influenza
Start: 2022-09-14End: 2024-01-05Updated: 2025-01-16
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
CompletedNCT05827978
ModernaTX, Inc.Seasonal Influenza
Start: 2023-04-17End: 2024-06-24Updated: 2025-07-10
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
CompletedNCT06602024
ModernaTX, Inc.Seasonal Influenza
Start: 2024-09-16End: 2025-08-21Updated: 2026-09-16

Phase 4

A Study of Updated mRNA Seasonal Influenza Vaccines
Not yet recruitingNCT07884175
ModernaTX, Inc.Seasonal Influenza
Start: 2026-10-15End: 2026-12-07Target: 200Updated: 2026-10-20

Related Papers

Optimized seasonal influenza mRNA vaccine compositions demonstrate safety and enhanced immunogenicity in a phase 2 study
Figshare2026-07-13
Optimized seasonal influenza mRNA vaccine compositions demonstrate safety and enhanced immunogenicity in a phase 2 study
Figshare2026-07-13
Optimized seasonal influenza mRNA vaccine compositions demonstrate safety and enhanced immunogenicity in a phase 2 study.
2026-07-13
An mRNA influenza vaccine induces immunity comparable to an adjuvanted vaccine in a randomized trial.
2026-01-14
P-1454. mRNA-Based Respiratory Syncytial Virus Vaccine mRNA-1345 Induces Robust, Polyfunctional, and Durable CD4+ and CD8+ T Cell Responses with Similar Features in Adults Across Age Groups
Open Forum Infectious Diseases2026-01-01
P-1453. Characterization of longitudinal humoral and cellular immunogenicity following 2 or 3 doses of an mRNA-based cytomegalovirus vaccine in healthy adults
Open Forum Infectious Diseases2026-01-01
P-1452. A Seasonal Influenza Hemagglutinin mRNA-Based Vaccine Induces Humoral and Cellular Immunity Comparable to an Adjuvanted Inactivated Influenza Virus Vaccine
Open Forum Infectious Diseases2026-01-01
229. mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged ≥50 Years
Open Forum Infectious Diseases2026-01-01
mRNA-1010 influenza vaccine elicits distinct and enhanced humoral immunity compared to adjuvanted inactivated vaccines.
2025-12-15
An mRNA-based cytomegalovirus vaccine induces robust T-cell immune responses in cytomegalovirus-seropositive adults who have undergone allogeneic hematopoietic cell transplantation
Blood2025-11-03
Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.
2025-07-013 citations
Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study
Frontiers in Immunology2025-04-105 citations
An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers
Human Vaccines & Immunotherapeutics2025-04-0213 citations
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.
2025-02-0719 citations
Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trial.
2024-09-059 citations
Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial
The Journal of Infectious Diseases2024-06-2737 citations
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis.
2023-06-1984 citations